Medicenna’s New Leap: Boston Expansion and Leadership Reinforcements August 14, 2023
New Leadership in Boston: Harnessing Biotech’s Best Medicenna Therapeutics Corp., a pioneering clinical-stage immunotherapy company, has initiated its Boston expansion, aiming to tap into the leading biotech talent pool. Central to this effort is the recruitment of Brent Meadows, an industry stalwart with over a quarter-century in biotech and pharma.
Brent Meadows: A New Era for Medicenna Stepping in as the Chief Business Officer, Meadows is no stranger to the industry’s intricacies. With a decorated history spanning giants like Johnson & Johnson, Regeneron, and Bristol-Myers Squibb, he’s well-positioned to navigate Medicenna’s ambitious growth.
Meadows’ mandate is clear: steer Medicenna’s business vision and craft pivotal partnerships, focusing on the promising Phase 3 glioblastoma treatment, bizaxofusp, and the burgeoning Superkines pipeline.
Reflecting on this strategic hiring, Dr. Fahar Merchant, Medicenna’s CEO, remarked, “As we shape our Bostonian leadership vision, Brent’s expertise stands out. His legacy in oncology transactions will be pivotal as we approach major milestones, aiming to revolutionize patient treatment.”
Echoing the enthusiasm, Meadows commented on his vision for Medicenna, highlighting the promising potential of bizaxofusp in battling the severe brain cancer form, recurrent GBM.
Strengthened Management for a Robust Future Medicenna isn’t stopping at just one significant appointment. Delphine Davan has been ushered in as the VP of Investor Relations, while Eamonn Peters has been elevated to VP of Finance. With Evelyn Pau overseeing External Collaborations and Minh To leading Oncology Research, the future looks radiant.
However, transitions often come with farewells. Elizabeth Williams, the CFO who lent her expertise for over six years, is venturing into new biotech terrains. Appreciating her dedication, Dr. Merchant wished her success, emphasizing that Medicenna’s evolution hinges on dedicated professionals.
Medicenna: A Glimpse into the Future Specializing in innovative Superkines versions, Medicenna is shaping the future of immunotherapy. Their IL-2 Superkine, MDNA11, represents next-gen solutions, targeting cancer’s most challenging forms, including recurrent GBM. With FastTrack and Orphan Drug accolades, Medicenna’s path is clear: turning “cold” tumors into history.
Forward Looking Statements This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements, including statements on the development and potential of the Superkines, on any potential benefits that may be realized as a result of new members of the management team, on its growth and business development, financing and clinical activities, the access to top-biotech talent, the Company’s corporate strategy and value inflection milestones with MDNA11’s single-agent and combination dose expansion trials. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially,” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.
